SAA1 and amyloidosis: Circulating SAA levels in controls, AV sclerosis, and AS patients. Given that SAA amyloidosis is generally systemic and is the result of sustained abnormally high circulating levels of SAA, promoted by inflammation, we measured circulating SAA1 levels in the AS patients, AV sclerosis patients, and controls.